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Confusing AD and dementia
• There is both public and professional conflation of AD and dementia
• Statistics you hear on prevalence of AD (5.8M Americans) means AD
dementia.
• Mild cognitive impairment due to Alzheimer’s disease is not being
counted here.
• CPT codes from ICD-9 and ICD-10 mean AD dementia.

DEMENTIA

MILD COGNITIVE IMPAIRMENT

PRESYMPTOMATIC AD

For every case of AD dementia
There are two cases of
preclinical Alzheimer’s disease.

Cognitive diagnosis
”What’s wrong with the mind”
Normal cognitive aging
Subjective impairment
Mild cognitive impairment
Mild dementia
Moderate dementia
Severe dementia

Causal diagnosis
”What’s wrong with the brain”
• Alzheimer’s disease
• Vascular brain injury
• Lewy body disease
• Frontotemporal degeneration
• Parkinson’s disease
• etc

Messaging for urgent action ….
AD: the only leading
cause of death that is
increasing

Excessive
narrative of
loss !

6 million people with
AD in the US

Are we already making progress?

•

Even though the total number of cases of dementia
due to Alzheimers is increasing,

•

The rate of Alzheimer’s disease among aging people
has actually declined in U.S., Europe, Japan
– Correlates with more education
– Probably also reflects better primary care,
notably better control of hypertension

Wolters et al, Neurology 2020

Outline
1. Diagnosis of mild Alzheimer’s disease
2. Role of biomarkers in diagnosis of AD
3. Recent developments in anti-amyloid therapy of AD

What is cognitive aging?
Normal cognitive aging is change in memory, word retrieval, processing
speed, problem-solving, and other aspects of cognition due to aging
processes, as opposed to disease.
Slower cognition, functionally insignificant word finding trouble,
inefficient memory retrieval, less intense concentration and attention
Pathologic cognitive aging reflects the additional effects of disease.

Mild cognitive impairment

An intermediate state between typical aging and dementia

• Complaint/concern about a change in cognition
• Objective impairment in cognitive domain(s)
• Preserved functional independence
• (Or in practice, only mild dependence)

MCI: a state of risk for dementia
Risk of conversion to dementia is about 10%/yr
Asymptote is 70% conversion overall, over 5-10 yrs
Of these, about 2/3 of converters have Alzheimer’s dementia
And the remainder a non-AD dementia

What is
Alzheimer’s Disease?

Neurofibrillary
Tangles
(tau)

Amyloid
Plaques

Six stages of AD tau tangles

Tau/NFTs
• Early deposition in medial temporal lobe including hippocampus

Memory loss

• Then association cortex – especially posterior

• Primary cortex last, motor cortex spared Cognitive loss

Sensorimotor sparing

The central tendency in AD is for early
involvement of memory-related brain regions
The normal cognitive presentation of AD is
amnestic mild cognitive impairment
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Factors increasing risk of
conversion of MCI to dementia
• Amnestic profile of impairment
• Encoding problems (i.e. cueing does not help)
• Hippocampal atrophy at time of diagnosis
• Deficits extending beyond memory encoding
(multidomain aMCI)

Mcevoy and Brewer

Diagnosis of MCI: Key points
• Memory loss for recently encountered material is a usual leading
complaint in Alzheimer’s disease
• Give a measurable test of recent memory

• Not normal to be unable to recall registered words after a few minutes
• Definitely abnormal to be unable to recognize words in a multiple choice format

• Montreal Cognitive assessment (MoCA)
• Reasonably sensitive to MCI
• Score < 26 is abnormal

• For those with MCI, and MRI to determine whether there is
hippocampal atrophy can help with counseling on prognosis and
deciding whether to refer

Gotcha
• The prognosis of MCI is sensitive to its definition
• If there is no complaint, e.g. mild impairment is discovered through
screening, conversion is less robust and reversion often occurs
• Here one strategy is to consider an abnormal screening result to be a
baseline, and to see if there is change over time (e.g. one year)

The value of neuropsychological testing
• Neuropsychological testing is recommended for suspected MCI
• Especially if there is a high level of baseline function
• Especially if there are potentially developmental factors

• Strengths of this approach are:
• Quantification, with implication that it establishes a clear baseline for followup
• Systematic evaluation of possibly subtle impairments in other domains
• Methods for estimating premorbid functioning make this approach well suited
to those with high or low intellectual baselines

Finnish Geriatric Intervention Study to Prevent
Cognitive Impairment and Disability (FINGER)
• 1260 at risk Finnish seniors
CAIDE > 6
• Interventions:
•
•
•
•

diet,
exercise,
cognitive training,
vascular risk monitoring

Disease-modifying medication ?
Symptomatic medication
Dementia-Friendly Community
Leverage Retained Strengths
Compensation
Build Cognitive Reserve
Vascular health
Mental health/Social belonging/Purpose
Sleep/Nutrition/Exercise/Cognitive activity
Cognitive
Age

Preclinical
Normal cognition
Subjective memory concerns
Aging

Mild cognitive impairment
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Importance of amyloid
plaques and tau tangles
• Defining hallmarks of Alzheimer’s disease
• Biomarkers (Measures) of Alzheimer’s disease
• Pathological drivers of Alzheimer’s disease?

Biomarkers
Measureable characteristics that signify disease processes
Imaging tests – MRI, PET
Spinal fluid protein levels

A |T |N biomarkers
A:

AMYLOID

T:

TAU

• Low amyloid protein in Cerebrospinal Fluid
• Amyloid PET

• High phosphorylated tau in CSF
• Tau PET

(N): NEURODEGENERATION

• Atrophy detected by MRI
• Low metabolism detected by FDG PET
• High total tau in CSF
Jack et al , 2018

25% Amyloid Positive at Age 70

Langbaum, J. B. et al. (2013) Ushering in the study and treatment of preclinical Alzheimer disease
Nat. Rev. Neurol. doi:10.1038/nrneurol.2013.107

Degree of Abnormality

Canonical Sequence of AD Biomarkers

Latent/Presymptomatic

aMCI

Dementia
Jack et al, 2013

Amyloid PET scans
NEGATIVE – NOT ALZHEIMER’S

POSITIVE – ALZHEIMER’S PLAQUES

• AT(N) radically respects the difference
between syndrome and disease
• AT(N) defines specific biological states,
targetable by interventions
• AT(N) operationalizes preclinical AD

Conversion of aMCI to dementia

Mcevoy and Brewer

Plasma amyloid biomarkers
Schindler et al 2019

Appropriate clinical use of A |T |N biomarkers?
• Atypical dementia

• Young onset
• Nonamnestic profile
• AD vs FTD

• Confounding neurological processes

• Dementia in multiple sclerosis
• Older age epilepsy and cognitive impairment

• Persistent unexplained MCI
• In other words, in a specialty clinic
• But what if there is a treatment implication?

Primary Age-related tauopathy (PART)

Limbic-predominant Age-related
TDP-43 disEase (LATE)

• Degenerative hippocampal sclerosis
• TDP-43 proteinopathy
• A cause of amyloid-negative
amnestic MCI and amnestic
dementia
• Incidence ~ 50% by age 85

Crary et al
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Importance of amyloid
plaques and tau tangles
• Defining hallmarks of Alzheimer’s disease
• Biomarkers (Measures) of Alzheimer’s disease
• Pathological drivers of Alzheimer’s disease?

Amyloid cascade hypothesis
• Deposition of amyloid beta initiates Alzheimer
pathophysiology.
• Amyloid beta exerts a toxic effect on its neuronal
environment, possibly as soluble oligomers
• Neuritic transformation of plaques and intracellular
neurofibrillary pathology are secondary to amyloid effects.

Degree of Abnormality

Canonical Sequence of AD Biomarkers
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Dementia
Jack et al, 2013
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Anti-amyloid monoclonal antibodies “mabs”
Bapineuzumab - Pfizer
Solanezumab – Lilly
Gantenerumab – Hoffman-La Roche
Aducanamab - Biogen
Donanemab – Lilly/Eisai

Emerge and Engage Phase 3 Studies
• 50-85 y/o
• MCI due to AD ( most), mild AD (small percentage)
• CDR 0.5, MMSE 24-30
• MRI without > 4 microhemorrhages
> 1 lacune
> grade 3 white matter hyperintensities
i.e. very mild AD, with minimal vascular component

Figure 1

Amyloid Mabs really do clear amyloid !

Biological Psychiatry 2018 83311-319DOI: (10.1016/j.biopsych.2017.08.010)

Sevigny et al
Nature, 2016

Clinical Endpoints not met, esp. in ENGAGE

Adverse Events : ARIA
amyloid-related imaging abnormalities

FDA decision
• Accelerated approval based on biomarker evidence indicating a likely
effect
• Post approval Phase IV randomized trial required
• But … the CMS preliminary national coverage determination is now
restricts coverage to a context of Clinical Evidence Development,
i.e. a clinical trial

The controversy in a nutshell
• Aducanamab removes amyloid protein from the brain
• No clear-cut efficacy on cognition
• Politicization of the approval processes
• Mistakes were made
• CMS decision effectively severely restricts availability

Why do I bring this to your attention?
• As a class, anti-amyloid antibodies are likely to gain a role as more
evidence develops
• Converging evidence across trials
• Evidence of favorable effect on “downstream” tau biomarkers

• These will target early disease, underscoring the value of making a
diagnosis at MCI stage or earlier, which is our focus today
• Demonstrates the value of biomarkers in diagnosis and tracking
disease

Donanemab (Lilly)
• Phase 2 (TRAILBLAZER) met primary endpoint on slowing decline
• Now moves in Phase 3
• Like aducanamab, significantly reduces amyloid burden
• Similar safety risk profile, rates of ARIA
• Also appears to slow the rate of NFT accumulation (by tau-PET scans)

Hansson et al, Clinical Trials in Alzheimer’s Disease (CTAD) Conference, 2021

Hansson et al, Clinical Trials in Alzheimer’s Disease (CTAD) Conference, 2021

Summary
• Consistency across studies of aducanamab and donanemab on
biomarkers and (mild) cognitive effects
• The ARIA “side-effects” mandate biomarker confirmation of
treatment candidates and expensive monitoring
• Only for MCI/mild AD
• Tau markers emerging as key progression markers
• Expect increasing focus on identification of disease in what formerly
preclinical state, in the context of primary care.

Disease-modifying
medication ?
Disease-modifying
medication
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Dementia-Friendly Community
Leverage Retained Strengths
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Visit the Memory Hub and the Frye Art Museum
Contribute your ideas, talent, and support
Volunteer with The Memory Hub:
Contact Mari Becker, Program Manager of Community Education & Impact
(206) 744-2017, mbecker1@uw.edu
Clinical appointments –Memory and Brain Wellness Center at Harborview
(206) 520-5000 “First call appointing”
Participate in a research study:
Contact Jessica McDougall, ADRC Lead Research Coordinator
(206) 744-0588, uwadrc@uw.edu

depts.washington.edu/MBWC

Questions?

